Alon Doron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alon Doron has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Firas Fahoum
EEG and Epilepsy Unit, Department of Neurology Tel Aviv Sourasky Medical Center Tel Aviv Israel
2 shared publications - Lilach Goldstein
EEG and Epilepsy Unit, Department of Neurology Tel Aviv Sourasky Medical Center Tel Aviv Israel
2 shared publications Amir Sonnenblick
Gray Faculty of Medical and Health Science, Tel Aviv University , Tel Aviv
1 shared publication- Amit Iton-Schwartz
Division of Dermatology, Rabin Medical Center – Beilinson Hospital , Petach Tikva
1 shared publication - Arnon Karni
Tel Aviv University
1 shared publication Aviv Barzilai
Gray Faculty of Medical and Health Science, Tel Aviv University , Tel Aviv
1 shared publication
Latest Publications
- 31 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (3) , 427-434
Vitiligo-like leucoderma following treatment with cyclin-dependent kinase 4 and 6 inhibitors: analysis of clinicopathological and immunohistochemical findings
Background: Vitiligo-like leucoderma is a rare cutaneous adverse event associated with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. However, its clinicopathological and immunohistochemical profiles remain unclear. Objectives: To characterize the clinical, pathological and immunohistochemical features of CDK4/6 inhibitor-induced vitiligo-like leucoderma. Methods: This retrospective case series describes five female patients with advanced or metastatic breast cancer who developed vitiligo-like leucoderma during CDK4/6 inhibitor therapy. Clinical data and skin biopsies were evaluated, including immunohistochemical analysis of melanocyte markers, cell-cycle protein (p16) and T-cell subsets. Results: The depigmented lesions appeared primarily in sun-exposed areas. Two patients exhibited an inflammatory phenotype with pruritus and a lichenoid rash. In all patients, the lesions progressed rapidly over several months and then stabilized. This course was maintained regardless of any vitiligo-targeted therapeutic interventions. Histopathological examination revealed complete absence of melanocytes in all biopsies. Three specimens (60%) had inflammatory changes, including lichenoid and perivascular lymphohistiocytic infiltrates, with immunohistochemistry showing a predominance of CD4+ T cells within the infiltrates. Features of chronic actinic damage (epidermal atrophy, orthokeratosis, reactive keratinocytes, dermal solar elastosis) were observed. In two biopsies (40%), there was a patchy distribution of p16 staining within basal and suprabasal keratinocytes. Four patients (80%) demonstrated prolonged (2–4 years) progression-free survival. Conclusions: CDK4/6 inhibitor-induced vitiligo-like leucoderma appears to be a distinct clinicopathological entity, characterized by a predictable course and stabilization, consistent inflammatory features, and a CD4-predominant immune profile. These findings suggest a unique pathogenic mechanism, either immune-mediated or associated with actinic damage, that distinguishes this condition from classic vitiligo and immune checkpoint inhibitor-induced vitiligo-like leucoderma.
- 31 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (3) , 427-434
Vitiligo-like leucoderma following treatment with cyclin-dependent kinase 4 and 6 inhibitors: analysis of clinicopathological and immunohistochemical findings
Background: Vitiligo-like leucoderma is a rare cutaneous adverse event associated with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. However, its clinicopathological and immunohistochemical profiles remain unclear. Objectives: To characterize the clinical, pathological and immunohistochemical features of CDK4/6 inhibitor-induced vitiligo-like leucoderma. Methods: This retrospective case series describes five female patients with advanced or metastatic breast cancer who developed vitiligo-like leucoderma during CDK4/6 inhibitor therapy. Clinical data and skin biopsies were evaluated, including immunohistochemical analysis of melanocyte markers, cell-cycle protein (p16) and T-cell subsets. Results: The depigmented lesions appeared primarily in sun-exposed areas. Two patients exhibited an inflammatory phenotype with pruritus and a lichenoid rash. In all patients, the lesions progressed rapidly over several months and then stabilized. This course was maintained regardless of any vitiligo-targeted therapeutic interventions. Histopathological examination revealed complete absence of melanocytes in all biopsies. Three specimens (60%) had inflammatory changes, including lichenoid and perivascular lymphohistiocytic infiltrates, with immunohistochemistry showing a predominance of CD4+ T cells within the infiltrates. Features of chronic actinic damage (epidermal atrophy, orthokeratosis, reactive keratinocytes, dermal solar elastosis) were observed. In two biopsies (40%), there was a patchy distribution of p16 staining within basal and suprabasal keratinocytes. Four patients (80%) demonstrated prolonged (2–4 years) progression-free survival. Conclusions: CDK4/6 inhibitor-induced vitiligo-like leucoderma appears to be a distinct clinicopathological entity, characterized by a predictable course and stabilization, consistent inflammatory features, and a CD4-predominant immune profile. These findings suggest a unique pathogenic mechanism, either immune-mediated or associated with actinic damage, that distinguishes this condition from classic vitiligo and immune checkpoint inhibitor-induced vitiligo-like leucoderma.
- Open Access
- 27 June 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173
Stress and seizures: The October 7th experience
- 27 June 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173
Open AccessStress and seizures: The October 7th experience
- 29 August 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 233, 107952
The COVID-19 pfizer BioNTech mRNA vaccine and the frequency of seizures
- 29 August 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 233, 107952
The COVID-19 pfizer BioNTech mRNA vaccine and the frequency of seizures
- 30 July 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6193-6201
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves
COVID-19 affects the respiratory parenchyma and may potentially contribute to the tendency of myasthenia gravis (MG) patients to develop respiratory failure. It is, therefore, important to study the safety of vaccines against SARS-CoV-2 and to assess the risk of COVID-19 in MG patients. The safety of the three-dose BNT162b2 mRNA vaccine and outcomes of COVID-19 during the alpha, delta, and omicron waves were studied in MG patients as well as the rate of exacerbations and safety for a period of up to 6 weeks from each vaccine dose and patient morbidity and mortality during COVID-19 compared to the general population. 430 vaccine doses were administered across 150 patients. Thirteen patients (8.7%) complained of exacerbation within 6 weeks of each vaccine dose. Both MG onset rate and exacerbation rate were similar to previous years. MG exacerbation rate among fifteen patients who had COVID-19 was significantly higher (40%) compared to the rate following vaccination. During the alpha and delta waves, COVID-19 mortality and severe disease were significantly higher (26.7%) compared to the general population (0.96%). All of them were unvaccinated and had generalized MG. During the omicron wave, all the MG patients who contracted COVID-19 were vaccinated and had mild disease. We concluded that COVID-19 is hazardous for generalized MG patients, while the vaccination did not raise the risk for either exacerbation or new onset of MG and was associated with a reduced risk for severe COVID-19. Hence, it is recommended for generalized MG patients to get vaccinated.
- 30 July 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6193-6201
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves
COVID-19 affects the respiratory parenchyma and may potentially contribute to the tendency of myasthenia gravis (MG) patients to develop respiratory failure. It is, therefore, important to study the safety of vaccines against SARS-CoV-2 and to assess the risk of COVID-19 in MG patients. The safety of the three-dose BNT162b2 mRNA vaccine and outcomes of COVID-19 during the alpha, delta, and omicron waves were studied in MG patients as well as the rate of exacerbations and safety for a period of up to 6 weeks from each vaccine dose and patient morbidity and mortality during COVID-19 compared to the general population. 430 vaccine doses were administered across 150 patients. Thirteen patients (8.7%) complained of exacerbation within 6 weeks of each vaccine dose. Both MG onset rate and exacerbation rate were similar to previous years. MG exacerbation rate among fifteen patients who had COVID-19 was significantly higher (40%) compared to the rate following vaccination. During the alpha and delta waves, COVID-19 mortality and severe disease were significantly higher (26.7%) compared to the general population (0.96%). All of them were unvaccinated and had generalized MG. During the omicron wave, all the MG patients who contracted COVID-19 were vaccinated and had mild disease. We concluded that COVID-19 is hazardous for generalized MG patients, while the vaccination did not raise the risk for either exacerbation or new onset of MG and was associated with a reduced risk for severe COVID-19. Hence, it is recommended for generalized MG patients to get vaccinated.